Citation Impact
Citing Papers
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.
2007
Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials
2001
Male gynecomastia and risk for malignant tumours – a cohort study
2002
Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-Amino-17-demethoxygeldanamycin as Potent, Water-Soluble Inhibitors of Hsp90
2006
Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
1999
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
2005
Nanomedicine—Challenge and Perspectives
2009
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Multistage Nanoparticles for Improved Delivery into Tumor Tissue
2012 StandoutNobel
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
2002
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Effect of pegylation on pharmaceuticals
2003 Standout
Perifosine: Update on a novel Akt inhibitor
2009
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
2001
Delivery materials for siRNA therapeutics
2013 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Epigenetic control of gene expression: Potential implications for cancer treatment
2017
Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity
2002
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Cancer nanotechnology: opportunities and challenges
2005 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Liposome-based drug delivery in breast cancer treatment
2002
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience
2002
Male breast cancer
2006 Standout
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents
2012
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
2000
Congestive heart failure in patients treated with doxorubicin
2003 Standout
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin
2001
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer
2002
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
2003
Application of liposomal technologies for delivery of platinum analogs in oncology
2013
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises
2008
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer
2004
The molecular landscape of head and neck cancer
2018 Standout
Mussel-inspired protein-mediated surface functionalization of electrospun nanofibers for pH-responsive drug delivery
2013
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
2014
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Cardiac safety of liposomal anthracyclines
2004
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
2013 Standout
Designing dendrimers for biological applications
2005 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
2004
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
2000
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer
2001
Prospects for the use of electrochemical methods for the destruction of aromatic organochlorine wastes
1997
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications
2019 Standout
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
2008
Second-Line Treatment of Ovarian Cancer
2000
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
2001
Shrink-Wrap Vesicles
2005 StandoutNobel
Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors
2005
The composition of the Earth
1995 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer
2003
The Lu-Hf isotope geochemistry of chondrites and the evolution of the mantle-crust system
1997 Standout
Single and Coupled Electrochemical Processes and Reactors for the Abatement of Organic Water Pollutants: A Critical Review
2015 Standout
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
2005
Experimental determination of element partitioning between silicate perovskites, garnets and liquids: constraints on early differentiation of the mantle
1988
Descriptive and Prognostic Value of Patient-Reported Outcomes: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma
2006
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study
2002
Mantle geochemistry: the message from oceanic volcanism
1997 StandoutNature
Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
2008
Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck
2001
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Multiple Myeloma
2011 Standout
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
1999
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
2002 Standout
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents
2005
Works of PG Richardson being referenced
A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).
2001
The determination of absolute electron affinities of chlorobenzenes, chloronaphthalenes and chlorinated biphenyls from reduction potentials
1991
Phase identification, microstructural characterization, phase microanalyses and leaching performance evaluation of SYNROC-FA crystalline ceramic waste form
1987
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin
1998
Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM)
2005
Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)
2008
Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity
2005
Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study
2005
PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
2011
Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men
1991